Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

Exclusion Criteria

• •1. Use of intravenous steroid pulse therapy or intravenous immunoglobulin or plasma exchange/adsorption within 3 weeks prior to Screening.
• •2. Use of tocilizumab, satralizumab, belimumab, ofatumumab within 1 months prior to Screening.
• •3. Patients treated with oral immunosuppressive agents other than steroids (e.g. azathioprine, mycophenolate mofetil, methotrexate, tacrolimus, cyclosporine in the 3 months prior to allocation.
• •4. Use of rituximab or inebilizumab within 6 months prior to Screening.
• •5. Patients infected with hepatitis B or C virus, or human immunodeficiency virus, or those having active infectious diseases.
• •6. Patients with a severe chronic infection or a history of recurrent infections.
• •7. Patients with a history of radiation treatment (whole body irradiation or lymphoid irradiation) or stem cell transplantation.
• •8. Patients who are pregnant or breast-feeding.
• •9. Patients who are participating in other clinical trials for NMOSD.
• •10. Patients diagnosed with cancer.